JP2024546989A5 - - Google Patents

Info

Publication number
JP2024546989A5
JP2024546989A5 JP2024536119A JP2024536119A JP2024546989A5 JP 2024546989 A5 JP2024546989 A5 JP 2024546989A5 JP 2024536119 A JP2024536119 A JP 2024536119A JP 2024536119 A JP2024536119 A JP 2024536119A JP 2024546989 A5 JP2024546989 A5 JP 2024546989A5
Authority
JP
Japan
Prior art keywords
composition according
subject
disorder
suffering
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024536119A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024546989A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/081558 external-priority patent/WO2023114846A1/en
Publication of JP2024546989A publication Critical patent/JP2024546989A/ja
Publication of JP2024546989A5 publication Critical patent/JP2024546989A5/ja
Pending legal-status Critical Current

Links

JP2024536119A 2021-12-15 2022-12-14 治療用ペプチドの使用 Pending JP2024546989A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163289915P 2021-12-15 2021-12-15
US63/289,915 2021-12-15
PCT/US2022/081558 WO2023114846A1 (en) 2021-12-15 2022-12-14 Uses of therapeutic peptides

Publications (2)

Publication Number Publication Date
JP2024546989A JP2024546989A (ja) 2024-12-26
JP2024546989A5 true JP2024546989A5 (https=) 2025-12-22

Family

ID=85157076

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024536119A Pending JP2024546989A (ja) 2021-12-15 2022-12-14 治療用ペプチドの使用

Country Status (5)

Country Link
US (1) US20250059233A1 (https=)
EP (1) EP4447987A1 (https=)
JP (1) JP2024546989A (https=)
CN (1) CN118785917A (https=)
WO (1) WO2023114846A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10280202B2 (en) * 2015-03-02 2019-05-07 Kyoto University Peptide
WO2018047852A1 (en) 2016-09-07 2018-03-15 Kyoto University Peptides and peptide conjugates for treating mental disorders
WO2021100614A1 (ja) * 2019-11-19 2021-05-27 国立大学法人京都大学 大豆ペプチド及び／又はコラーゲンペプチド含有神経心理学的機能改善剤
JP7787424B2 (ja) * 2021-02-04 2025-12-17 ユーハ味覚糖株式会社 デプレスタチン含有組成物の製造方法
JPWO2022186015A1 (https=) * 2021-03-02 2022-09-09
WO2022202985A1 (ja) * 2021-03-24 2022-09-29 森永乳業株式会社 ペプチド、及び該ペプチドを有効成分として含有する組成物

Similar Documents

Publication Publication Date Title
AU2021201034B2 (en) Sublingual formulation of riluzole
Gori et al. Sleep quality, chronotypes and preferential timing of attacks in migraine without aura
US20100168120A1 (en) Salts of pyridazine compounds
Masia et al. Epilepsy and behavior: a brief history
JP2005506370A5 (https=)
KR20250005181A (ko) 인지 기능장애 치료
JP2025511084A (ja) 睡眠障害の処置に使用するための５－ｍｅｏ－ｄｍｔ
JP2022515766A5 (https=)
JP2019534327A5 (https=)
JP2012508254A (ja) α７選択的リガンドを用いる治療
US20200262864A1 (en) Deuterated forms of aminosterols and methods of using the same
JP2016023188A5 (https=)
JP2023546238A (ja) 慢性的なｓｓｒｉレジメンの後にシロシビンに対する感受性を高めるためのベンゾジアゼピンの使用
JP2024546989A5 (https=)
Mascherpa et al. Vulvodynia as a possible somatization disorder. More than just an opinion
JP2024520132A5 (https=)
WO2017119456A1 (ja) せん妄の予防または治療剤
JP2024511997A5 (https=)
Sangroula et al. Neuropsychiatric debut as a presentation of Guillain-Barré Syndrome: an atypical clinical case and literature review
Yoon et al. Delusional parasitosis in a patient with an infarction in the territory of the right posterior cerebral artery
JP2025509432A5 (https=)
Medvedev et al. Antidepressant and anxiolytic efficacy and tolerability of agomelatine in the treatment of depression after COVID-19 in daily clinical practice (non-interventional study TELESPHOR)
JP2025541312A (ja) Ａｖｐｒ１ａアゴニストの用途
US20250059233A1 (en) Use of therapeutic peptides
Salkade Trigeminal and cervical radiculitis after tozinameran vaccination against COVID-19